Amyvid Training Issues Lead To Complete Response Letter, Could Force More Trials
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA says consistent training program needed for market implementation of amyloid diagnostic. Lilly says issues will be resolved promptly.